drugset
drugset / Trial / NCT06247488

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488 ↗

Phase 4 Completed 110 enrolled Arbor Pharmaceuticals, Inc.
RandomizedCrossoverQuadruple-blindOther

Summary

The purpose of this study is to assess the abuse potential of gabapentin enacarbil immediate release capsules taken alone and in combination with oxycodone in healthy adult, non-dependent, recreational opioid users.

Timeline

Start
2022-01-31
Primary completion
2023-04-25
Completion
2023-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject GE-IR Unknown 200 mg Oral
Subject GE-IR Unknown 450 mg Oral
Subject Oxycodone Other / unclassified 20 mg Oral

Indications

substance abuse